Prognostic Impact of Mesenteric Lymph Node Status on Digestive Resection Specimens During Cytoreductive Surgery for Ovarian Peritoneal Metastases.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
05
06
2023
accepted:
17
09
2023
medline:
7
12
2023
pubmed:
22
10
2023
entrez:
22
10
2023
Statut:
ppublish
Résumé
The most common mode of ovarian cancer (OC) spread is intraperitoneal dissemination, with the peritoneum as the primary site of metastasis. Cytoreductive surgery (CRS) with chemotherapy is the primary treatment. When necessary, a digestive resection can be performed, but the role of mesenteric lymph nodes (MLNs) in advanced OC remains unclear, and its significance in treatment and follow-up evaluation remains to be determined. This study aimed to evaluate the prevalence of MLN involvement in patients who underwent digestive resection for OC peritoneal metastases (PM) and to investigate its potential prognostic value. This retrospective, descriptive study included patients who underwent CRS with curative intent for OC with PM between 1 January 2007 and 31 December 2020. The study assessed MLN status and other clinicopathologic features to determine their prognostic value in relation to overall survival (OS) and progression-free survival (PFS). The study enrolled 159 women with advanced OC, 77 (48.4%) of whom had a digestive resection. For 61.1% of the patients who underwent digestive resection, MLNs were examined and found to be positive in 56.8%. No statistically significant associations were found between MLN status and OS (p = 0.497) or PFS ((p = 0.659). In anatomopathologic studies, MLNs are not systematically investigated but are frequently involved. In the current study, no statistically significant associations were found between MLN status and OS or PFS. Further prospective studies with a systematic and standardized approach should be performed to confirm these findings.
Sections du résumé
BACKGROUND
BACKGROUND
The most common mode of ovarian cancer (OC) spread is intraperitoneal dissemination, with the peritoneum as the primary site of metastasis. Cytoreductive surgery (CRS) with chemotherapy is the primary treatment. When necessary, a digestive resection can be performed, but the role of mesenteric lymph nodes (MLNs) in advanced OC remains unclear, and its significance in treatment and follow-up evaluation remains to be determined. This study aimed to evaluate the prevalence of MLN involvement in patients who underwent digestive resection for OC peritoneal metastases (PM) and to investigate its potential prognostic value.
METHODS
METHODS
This retrospective, descriptive study included patients who underwent CRS with curative intent for OC with PM between 1 January 2007 and 31 December 2020. The study assessed MLN status and other clinicopathologic features to determine their prognostic value in relation to overall survival (OS) and progression-free survival (PFS).
RESULTS
RESULTS
The study enrolled 159 women with advanced OC, 77 (48.4%) of whom had a digestive resection. For 61.1% of the patients who underwent digestive resection, MLNs were examined and found to be positive in 56.8%. No statistically significant associations were found between MLN status and OS (p = 0.497) or PFS ((p = 0.659).
CONCLUSIONS
CONCLUSIONS
In anatomopathologic studies, MLNs are not systematically investigated but are frequently involved. In the current study, no statistically significant associations were found between MLN status and OS or PFS. Further prospective studies with a systematic and standardized approach should be performed to confirm these findings.
Identifiants
pubmed: 37865938
doi: 10.1245/s10434-023-14405-3
pii: 10.1245/s10434-023-14405-3
pmc: PMC10695887
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
605-613Informations de copyright
© 2023. The Author(s).
Références
Arch Gynecol Obstet. 2018 Apr;297(4):997-1004
pubmed: 29380107
Gynecol Oncol. 1995 Nov;59(2):200-6
pubmed: 7590473
Eur J Surg Oncol. 2012 Feb;38(2):170-5
pubmed: 22104389
Cochrane Database Syst Rev. 2021 Jul 30;7:CD005343
pubmed: 34328210
J Natl Cancer Inst. 2005 Apr 20;97(8):560-6
pubmed: 15840878
J Surg Oncol. 2011 Sep 1;104(3):250-4
pubmed: 21472733
Ann Chir. 2000 Feb;125(2):163-72
pubmed: 10998803
Am J Obstet Gynecol. 2017 Sep;217(3):334.e1-334.e9
pubmed: 28549976
J Visc Surg. 2020 Apr;157(2):79-86
pubmed: 31837942
J Gastrointest Surg. 2009 Jul;13(7):1337-44
pubmed: 19418101
Ann Surg Oncol. 2007 Dec;14(12):3552-7
pubmed: 17896149
N Engl J Med. 2019 Feb 28;380(9):822-832
pubmed: 30811909
J Natl Cancer Inst. 2007 Mar 21;99(6):433-41
pubmed: 17374833
J Gastrointest Oncol. 2021 Aug;12(4):1285-1300
pubmed: 34532088
Eur J Surg Oncol. 2023 Sep;49(9):106911
pubmed: 37149402
Ann Surg Oncol. 2021 Nov;28(12):7606-7613
pubmed: 33821347
Jpn J Clin Oncol. 2020 Dec 16;50(12):1380-1385
pubmed: 32676635
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1:61-85
pubmed: 34669199
Cancer Chemother Pharmacol. 1999;43 Suppl:S15-25
pubmed: 10357554
Eur J Gynaecol Oncol. 2004;25(2):169-74
pubmed: 15032274
Gynecol Oncol. 2003 Aug;90(2):390-6
pubmed: 12893206
Ann Oncol. 2017 Apr 1;28(4):711-717
pubmed: 28327917
Ann Surg Oncol. 2022 Apr;29(4):2561-2569
pubmed: 34890024
Ann Surg Oncol. 2014 Jul;21(7):2369-75
pubmed: 24558070
Pleura Peritoneum. 2023 May 16;8(3):133-138
pubmed: 37662604
Surg Today. 2021 Jan;51(1):101-110
pubmed: 32754844
Br J Surg. 2018 Jan;105(2):e99-e109
pubmed: 29341159
World J Gastrointest Surg. 2016 Mar 27;8(3):179-92
pubmed: 27022445
Cancer. 2010 Jun 1;116(11):2571-80
pubmed: 20336791
Gynecol Oncol. 2012 May;125(2):483-92
pubmed: 22366151